BCAL Diagnostics Limited (ASX: BDX), an Australian early cancer detection company, has secured firm commitments for an additional $4.9 million under its existing $10 million Convertible Note Facility, alongside an expected $1.4 million first Tranche of its FY2026 Research and Development tax offset. The combined funding is designed to support the company's commercialisation activities and ongoing development of its blood-based cancer detection portfolio through the financial year 2027. The announcement, dated 29 June 2026, signals that BCAL has addressed its near-term funding requirements without resorting to a dilutive Equity raise for the additional Capital. Investors will be watching closely as the company advances several early-stage cancer detection products toward broader clinical and commercial adoption in Australia and New Zealand.

Key Points

  • Company: BCAL Diagnostics Limited (ASX: BDX)
  • Firm commitments secured for an additional $4.9 million under the existing $10 million Convertible Note facility
  • First tranche of FY2026 R&D tax offset of $1.4 million expected on or around 30 June 2026; balance of approximately $1.1 million expected in October 2026
  • Total expected FY2026 R&D tax offset is approximately $2.5 million; the $1.4 million first tranche represents approximately 56% of this amount
  • Funds support commercialisation strategy and planned activities through FY2027
  • Portfolio includes BREASTESTplus, Avantect Pancreatic, Avantect Ovarian, BREASTEST Monitor, and an Avantect multi-cancer test in development
  • Investors should watch for the October 2026 receipt of the remaining R&D tax offset balance and progress on commercialisation milestones

BCAL Diagnostics Draws on Existing $10 Million Convertible Note Facility for $4.9 Million Top-Up

BCAL Diagnostics has secured firm commitments for an additional $4.9 million under its existing $10 million Convertible Note facility, which was originally established in October 2025. The company stated that the additional funds will be drawn down as and when required, providing flexibility in how and when capital is deployed across its operations and development programs.

The structure of the drawdown arrangement is notable for its financial management implications. Rather than accessing the full committed amount in a single tranche, the ability to draw funds incrementally allows BCAL to align capital deployment with its actual expenditure requirements. This approach may help to manage interest obligations under the convertible note structure, though the specific terms of the note — including Interest Rate, conversion price, and Maturity date — were not detailed in this particular company update.

How the R&D Tax Offset Provides Non-Dilutive Funding for BCAL's Cancer Detection Research

Alongside the Convertible Note top-up, BCAL expects to receive the first tranche of its FY2026 Research and Development tax offset of $1.4 million on or around 30 June 2026. This represents approximately 56% of the company's total expected FY2026 R&D tax offset of approximately $2.5 million. The remaining balance of approximately $1.1 million is expected to be received in October 2026.

Chief Executive Officer Anne-Louise Arnett described the R&D tax offset as "an important source of non-dilutive funding" for BCAL. Non-dilutive funding is particularly significant for early-stage healthcare and diagnostics companies because it allows them to fund operations and development without issuing new shares, which would reduce the proportional ownership of existing shareholders. For a company at BCAL's stage of commercialisation, the ability to offset a portion of research expenditure through the government's tax incentive program provides a recurring and predictable source of cash inflow that supplements capital raised from investors.

Combined Funding Package Designed to Carry BCAL Through FY2027 Operations

BCAL stated that the combined funding from the Convertible Note top-up and the R&D tax offset supports the company's planned activities through FY2027. This is a meaningful forward-looking statement, as it suggests the company's board and management have assessed their projected cash requirements and determined that the secured funding is sufficient to meet those needs for the period ahead.

The announcement does not provide a detailed breakdown of how the funds will be allocated across specific programs, clinical activities, or commercialisation efforts. The company did not disclose a specific cash Burn Rate or projected runway beyond the general statement of funding adequacy through FY2027. Investors seeking a more granular picture of expenditure plans may look to BCAL's upcoming quarterly Cash Flow reports and annual financial statements for additional detail.

BREASTESTplus and Avantect Portfolio at the Centre of BCAL's Commercialisation Strategy

BCAL's early detection portfolio, which the funding is intended to support, includes BREASTESTplus — the company's flagship blood-based breast health test — as well as BREASTESTplus Version 2 and BREASTEST Monitor. BREASTESTplus was described in the company's background materials as a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women, particularly those with dense breasts. The test is designed to function as a 'rule-out' tool in the clinical evaluation of breast disease.

The portfolio also includes the Avantect suite of tests — Avantect Pancreatic, Avantect Ovarian, and an Avantect multi-cancer test that remains in development. These tests are offered under an exclusive licence with ClearNote Health Inc., a US-based precision diagnostics company, covering sales and distribution rights in Australia and New Zealand. The multi-cancer test, which is still in the development phase, represents a potentially significant long-term commercial opportunity if it proceeds through validation and regulatory pathways successfully.

CEO Anne-Louise Arnett on Accessibility of Blood-Based Cancer Testing for Doctors and Patients

In the company update, CEO Anne-Louise Arnett commented on both the financing milestone and BCAL's broader strategic direction. Arnett said the company was "delighted with the additional financing commitment for the balance of the Convertible Note facility" and highlighted that the R&D tax offset "continues to be an important source of non-dilutive funding for BCAL as we advance our early cancer detection portfolio."

Arnett also framed the funding in the context of the company's commercialisation focus, stating that the capital "supports our commercialisation strategy as we focus on making simple blood-based cancer tests more accessible to doctors and patients." This framing underscores that BCAL views its mission not only as a scientific or regulatory challenge, but also as a market access challenge — ensuring that its tests are adopted within clinical workflows by general practitioners, specialists, and patients across Australia and New Zealand.

What the Convertible Note Structure Means for BCAL Shareholders

Convertible notes are a form of Debt Financing that can, under specified conditions, be converted into equity. While the use of a convertible note facility avoids immediate dilution at the time funds are drawn, shareholders should be aware that conversion events — if and when they occur — could result in the issuance of new shares, which would have a dilutive effect. The specific conversion terms, including the conversion price and triggering conditions, were not restated in this company update; investors are referred to the original facility announcement from 20 October 2025 for those details.

The fact that BCAL was able to secure firm commitments for the full remaining balance of the $10 million facility may be interpreted as a signal of continued investor confidence in the company's direction. However, as with all early-stage healthcare investments, the convertible note structure carries risks related to repayment obligations if conversion does not occur, and the company's ability to service or repay the debt will depend on its future cash generation, additional capital raises, or continued access to non-dilutive funding sources such as the R&D tax offset program.

BCAL's R&D Tax Offset Timeline: $1.4 Million by 30 June 2026, Balance in October 2026

The timing of the R&D tax offset receipts is worth noting for investors monitoring BCAL's Liquidity position. The first tranche of $1.4 million is expected on or around 30 June 2026 — effectively the last day of the financial year — meaning this cash inflow is anticipated to land on BCAL's Balance Sheet as the company closes out FY2026. The remaining balance of the approximately $2.5 million total offset, which amounts to roughly $1.1 million, is expected to follow in October 2026.

The staggered nature of these receipts reflects the administrative processes associated with the Australian Government's R&D tax incentive program, which is administered jointly by the Australian Taxation Office and AusIndustry. For eligible companies, the program provides a tax offset on qualifying R&D expenditure, and for companies with annual turnover below a specified threshold, this offset is refundable — making it a genuine cash benefit rather than merely a tax reduction against income. BCAL has not disclosed the precise calculation basis for its $2.5 million estimated claim in this update.

BCAL's Exclusive ClearNote Health Licence and the Australian and New Zealand Market Opportunity

A key structural element of BCAL's commercial platform is its exclusive licence with ClearNote Health Inc. for the Avantect suite of blood-based cancer detection tests in Australia and New Zealand. ClearNote Health is described as a US-based precision diagnostics company, and the licence covers pancreatic, ovarian, and multi-cancer testing applications. Pancreatic and ovarian cancers are among the most challenging malignancies to detect at an early stage using conventional screening methods, which may create meaningful clinical Demand for sensitive and accessible blood-based alternatives.

The exclusivity of BCAL's licence for this geography provides a degree of commercial protection within Australia and New Zealand, limiting direct competition from ClearNote itself or other licensees in those markets. However, the commercial success of the Avantect platform will ultimately depend on factors including clinical validation data, regulatory approval pathways through the Therapeutic Goods Administration (TGA), reimbursement under Medicare or private Health Insurance, and adoption by the medical community. BCAL's company update does not provide a timeline for regulatory submissions or reimbursement applications for the Avantect products.

Upcoming Milestones Investors Will Be Watching Across BCAL's Cancer Detection Programs

With FY2027 funding now described as secured, attention is likely to shift toward BCAL's operational and clinical milestones over the coming months. The next near-term financial event is the receipt of the remaining R&D tax offset balance of approximately $1.1 million, expected in October 2026. Beyond that, investors may be watching for updates on the commercial uptake of BREASTESTplus among clinicians, the development progress of the Avantect multi-cancer test, and any data releases or regulatory developments relating to the broader portfolio.

The company's quarterly activity and cash flow reports, required under ASX Listing Rules for entities spending cash on operations, will provide the most regular visibility into BCAL's progress against its stated plans. Any announcements relating to clinical partnerships, distribution agreements, regulatory approvals, or reimbursement outcomes would represent significant potential catalysts for the company. The immediate share price impact of this funding announcement was not clear from available public information at the time of publication.